

# CONGENITAL CARDIOLOGY TODAY

Timely News and Information for BC/BE Congenital/Structural Cardiologists and Surgeons

Volume 10 / Issue 7

July 2012

North American Edition

## IN THIS ISSUE

### Biodegradable Devices for the Treatment of Congenital Cardiovascular Disease

by Daniel S. Levi, MD and Andrew L. Cheng, MD

~Page 1

### Highlights of Inaugural Breakout Session of PICES (Pediatric/ Congenital Interventional Cardiology Early-Career Society) at SCAI's Annual Meeting

by Brent M. Gordon, MD

~Page 10

## DEPARTMENTS

### Medical News, Products and Information

~Page 11

## UPCOMING MEDICAL MEETINGS

See website for additional meetings

**International Academy of Cardiology  
17th World Congress on Heart Disease  
Annual Scientific Sessions 2012**  
Jul. 27-30, 2012; Toronto Canada  
[www.cardiologyonline.com](http://www.cardiologyonline.com)

**ESC (European Society of Cardiology)  
Congress 2012**  
Aug. 25-29, 2012; Munich, Germany  
[www.escardio.org/congresses/esc-2012/](http://www.escardio.org/congresses/esc-2012/)

**2012 Specialty Review in Pediatric  
Cardiology Board Review/ CME Course**  
Sep. 10-14, 2012; Chicago, IL USA  
[www2.aap.org/sections/cardiology/pediatric\\_cardiology/2012/](http://www2.aap.org/sections/cardiology/pediatric_cardiology/2012/)

**Southeastern Pediatric Cardiovascular  
Society (SEPCS) Conference 2012**  
Sep. 13-15, 2012; Atlanta, GA USA  
[www.sepcs.org](http://www.sepcs.org)

**Florence International Symposium on  
Advances in Cardiomyopathies**  
Sep. 26-28, 2012; Florence, Italy  
[www.cardiomyopathies2012.com](http://www.cardiomyopathies2012.com)

## CONGENITAL CARDIOLOGY TODAY

Editorial and Subscription Offices

16 Cove Rd, Ste. 200

Westerly, RI 02891 USA

[www.CongenitalCardiologyToday.com](http://www.CongenitalCardiologyToday.com)

© 2012 by Congenital Cardiology Today ISSN:  
1544-7787 (print); 1544-0499 (online).  
Published monthly. All rights reserved.

Recruitment Ads on Pages: 4, 7, 9, 11,  
13, 14

Practice for Sale on Page: 8

## Biodegradable Devices for the Treatment of Congenital Cardiovascular Disease

By Daniel S. Levi, MD and Andrew L. Cheng, MD

Although biodegradable materials have been used in medicine for several decades, these materials only recently have been utilized for pediatric transcatheter and surgical vascular and cardiac devices. Most devices used to repair congenital heart lesions only need to serve as temporary scaffoldings; ideally, they would ultimately disappear.

Biodegradable implants have many potential advantages over conventional devices. The interest in these materials for pediatric applications is primarily to accommodate growth. Lesions such as coarctation of the aorta and pulmonary artery stenosis could be temporarily augmented with a bioresorbable stent, allowing time for remodeling. As the patient grows and the vessel regains adequate functionality, the stent is slowly resorbed. Eventual complete resorption of the stent avoids the complications associated with traditional stents and eliminates the possible need to remove the device in the future.

Biodegradable devices for congenital heart patients can also facilitate other interventions at the same site. Biodegradable stents and devices will completely avoid these "full metal jacket" situations and may even preserve side branches near the site of intervention. These

devices also will allow for improved radiographic imaging of lesions with MRI or CT.

***"Biodegradable implants have many potential advantages over conventional devices. The interest in these materials for pediatric applications is primarily to accommodate growth."***

Reduction or avoidance of late stent restenosis has been ascribed, at least to some degree, to inflammation around metallic struts after coronary stenting. Replacement of the conventional metallic scaffold with an absorbable biopolymer, therefore, theoretically should decrease the rate of restenosis. This has been the impetus for the maturation of biodegradable stent technology and currently a variety of biodegradable coronary stents are now being tested in the adult population. As many bioresorbable stents are embedded with drug-eluting agents, they may even provide an opportunity to improve results in stenting difficult lesions such as pulmonary vein stenoses.

## CONGENITAL CARDIOLOGY TODAY

## CALL FOR CASES AND OTHER ORIGINAL ARTICLES

Do you have interesting research results, observations, human interest stories, reports of meetings, etc. to share?

Submit your manuscript to: [RichardK@CCT.bz](mailto:RichardK@CCT.bz)

# SIZING UP THE FUTURE



## **X™ Line PTV Balloon Dilatation Catheters**

*Braided inner tubing and radiopaque marker bands for maintaining strength & trackability*

## **PTS® Sizing Balloon Catheters**

*For accurate measurement of selecting the appropriately sized occluder device*


## **NuCLEUS-X™**

### **PTV Balloon Dilatation Catheters**

*Variable waist expansion in the center of the balloon for accurate placement*



**The Center  
of It All**



**B. BRAUN**

*Interventional  
Systems*

B. Braun Interventional Systems Inc.  
824 Twelfth Avenue  
Bethlehem, PA 18018  
Tel: 1-877-VENA CAV (836-2228)  
Fax: 610-266-3982

[www.bisusa.org](http://www.bisusa.org)

Stent	Material	Coating	Design	Byproducts	Drug elution	Radio-opacity	Strut thickness, $\mu\text{m}$	Crossing profile, mm	Stent-to-artery coverage, %	Radial support duration	Absorption time
Igaki-Tamai	PLLA	None	Zig-zag helical coils with straight bridges	Lactic acid, $\text{CO}_2$ , $\text{H}_2\text{O}$	None	Gold markers	170	?	24	6 months	2 years
REVA	Poly(12DT E-12DT carbonate)	None	Slide and lock	L-tyrosine, ethanol, $\text{CO}_2$	None	Iodine impregnated	200	1.7	55	3-6 months	2 years
BTI	Salicylate + linker polymer	Salicylate + adipic acid	Tube with laser-cut voids	Salicylate, $\text{CO}_2$ , $\text{H}_2\text{O}$	Sirolimus, salicylate	None	200	2.0	65	3 months	6 months
BVS	PLLA	PDLLA	1.0: out-of-phase sinusoidal hoops with straight and direct links. 1.1: in-phase hoops with straight links	Lactic acid, $\text{CO}_2$ , $\text{H}_2\text{O}$	Everolimus	Platinum markers	156	1.4	25	1.0: weeks. 1.1: 3 months	2 years
AMS	Magnesium alloy	None	Sinusoidal in-phase hoops linked by straight bridges	N/A	None	None	165	1.2	10	Days-weeks	<4 months

## Biodegradable Stents

Biodegradable stents have been the most heavily investigated biodegradable cardiovascular devices to date. These devices have been hypothesized to cause a decreased incidence of late thrombosis, since they are eventually completely resorbed. The new generation of fully absorbable stents will, hopefully, minimize or completely eliminate late restenosis.

Like other drug-eluting stents (DES), biodegradable stents have the ability to deliver antiproliferative medications, such as sirolimus, directly to the site of disease. In the pediatric population, such devices may be particularly valuable for systemic or pulmonary vein stenting, as restenosis in this setting is extremely common.

Several biodegradable stents that have undergone clinical trials are discussed below (Table 1).

### Igaki-Tamai Stent

The Igaki-Tamai stent was the first absorbable stent to be implanted in a human. It is made from poly(L-lactic acid) (PLLA). Strut thickness and vessel coverage by the struts both are larger than conventional metal stents (Figure 1a). Absorption is by bulk erosion and results in release of lactic acid, which is metabolized through the Krebs cycle.




Figure 1: Biodegradable Stents. (a) The Igaki-Tamai stent, (b) the REVA stent, (c) the BTI Stent.

A first-in-man prospective nonrandomized clinical trial of the stent was performed in 50 patients with a low complication rate. Although no further human coronary implants have been performed with this stent, it is being explored for peripheral applications and is clearly the predecessor to the current generation of coronary and peripheral biodegradable stents.

### REVA Stent

The REVA stent is made from an absorbable tyrosine-derived polycarbonate polymer, configured in a slide and lock (ratchet)

structure that allows for expansion without deformation (Figure 1b). This design may allow for increased radial force in stents designed for pulmonary artery and coarctation stenting. The RESORB first-in-man trial was a prospective nonrandomized safety study with a non-drug-eluting version of the REVA stent. Poor outcomes were noted with higher-than-anticipated target lesion revascularization due mainly to reduced stent diameter. A subsequent iteration of this stent, the ReZolve stent, includes an antiproliferative agent and soon will be undergoing clinical testing in the RESTORE trial.





## Opportunities available in all facets of Pediatric Cardiology

HCA, the largest healthcare company in the US, owns and/or manages over 160 hospitals in 20 states. We have opportunities available for Pediatric Cardiologists, Cardiovascular Surgeons and specialties associated with Pediatric Cardiology in most of our markets.

Whether you are looking for your first position or somewhere to complete your career, chances are we have something that will fit your needs. Call or email today for more information.



Kathy Kyer

Pediatric Subspecialty Recruitment Manager

Kathleen.Kyer@HCAHealthcare.com

937.235.5890

### BTI Stent

The BTI stent is a bioabsorbable sirolimus-eluting stent. This device incorporates a polymer backbone made from repeating salicylate molecules (Figure 1c). Resorption of the device releases salicylic acid, which is anticipated to decrease the inflammation associated with PCI. The Whisper first-in-man trial of patients implanted with the BTI stent showed higher-than-expected neointimal hyperplasia. Thus, the design is currently being revised to include thinner struts, decreased wall coverage, and a higher dose of sirolimus.

### BVS Everolimus-Eluting Stent

The Bioresorbable Vascular Scaffold (BVS) everolimus-eluting stent is the first biodegradable stent to have comparable clinical and imaging outcomes to metallic DES 2 years after implantation (Figure 2a). The BVS stent is composed of a PLLA backbone with a coating of poly(D,L-lactic acid) (PDLLA) and the antiproliferative drug everolimus. A larger version of this stent – possibly one designed for peripheral interventions – could be the first stent widely used for palliation of congenital heart disease.




Figure 2: The BVS everolimus-eluting stent. (a) BVS 1.0, (b) BVS 1.1.

The ABSORB trials studied two different revisions of the stent. The ABSORB cohort, a first-in-man trial, was a prospective nonrandomized study of BVS stent revision 1.0. At 3 years post-implantation the ischemia-driven major adverse cardiac event rate was very favorable and there were no stent thromboses. No vessel shrinkage was seen at 6 months; however, angiographic late loss was similar to some metallic DES (Figure 3). Despite this shrinkage, the stent resisted negative remodeling well. In fact, between 6 months and 2 years lumen enlargement was detected. Vasoactivity in the stented segment was also noted in the small number of patients who were tested. These vessels showed vasoconstriction induced by methylethylergonovine maleate and vasodilation induced by nitroglycerin. This observation suggests that the return of a physiologic response to vasoactive stimuli and the potential for arterial dilation in response to local ischemia is possible with bioresorbable stents.

The ABSORB cohort B trial is a prospective nonrandomized study of BVS stent revision 1.1. Based on results seen with BVS 1.0, modifications were made to maintain the mechanical integrity of the stent up to 6 months with the goal of reducing scaffold shrinkage and eventual late luminal loss, and to reduce acute and late recoil. The overall performance of BVS 1.1 at 6 months was significantly improved over BVS 1.0.



Mayo School of Continuous Professional Development and Co-sponsored by Children's Hospital of Orange County  
**Pediatric Cardiology 2012 Review Course**

August 26-31, 2012; The Ritz-Carlton, Laguna Niguel - Dana Point, California

REGISTER ONLINE TODAY: [www.mayo.edu/cme/cardiovascular-diseases-2012r636](http://www.mayo.edu/cme/cardiovascular-diseases-2012r636)

# A perfect melody of compassionate hearts, innovative minds and skilled hands.



## Melody®

### TRANSCATHETER PULMONARY VALVE (TPV) THERAPY

Worldwide, over 3,000 congenital heart disease patients have benefited from Melody TPV therapy. We remain committed to providing innovative options for your clinical management of these patients over their lifetime.

Visit [www.Melody-TPV.com](http://www.Melody-TPV.com)  
and restore hope for your patients.

#### Melody® Transcatheter Pulmonary Valve Ensemble® Transcatheter Valve Delivery System

**Indications:** The Melody TPV is indicated for use in a dysfunctional Right Ventricular outflow Tract (RVOT) conduit ( $\geq 16$  mm in diameter when originally implanted) that is either regurgitant ( $\geq$  moderate) or stenotic (mean RVOT gradient  $\geq 35$  mm Hg).

**Contraindications:** None known.

#### Warnings/Precautions/Side Effects:

- DO NOT implant in the aortic or mitral position.
- DO NOT use if patient's anatomy precludes introduction of the valve, if the venous anatomy cannot accommodate a 22-Fr size introducer, or if there is significant obstruction of the central veins.
- DO NOT use if there are clinical or biological signs of infection including active endocarditis.
- Assessment of the coronary artery anatomy for the risk of coronary artery compression should be performed in all patients prior to deployment of the TPV.
- To minimize the risk of conduit rupture, do not use a balloon with a diameter greater than 110% of the nominal diameter (original implant size) of the conduit for pre-dilation of the intended site of deployment, or for deployment of the TPV.
- The potential for stent fracture should be considered in all patients who undergo TPV placement. Radiographic assessment of the stent with chest radiography or fluoroscopy should be included in the routine postoperative evaluation of patients who receive a TPV.

- If a stent fracture is detected, continued monitoring of the stent should be performed in conjunction with clinically appropriate hemodynamic assessment. In patients with stent fracture and significant associated RVOT obstruction or regurgitation, reintervention should be considered in accordance with usual clinical practice.

Potential procedural complications that may result from implantation of the Melody device include: rupture of the RVOT conduit, compression of a coronary artery, perforation of a major blood vessel, embolization or migration of the device, perforation of a heart chamber, arrhythmias, allergic reaction to contrast media, cerebrovascular events (TIA, CVA), infection/sepsis, fever, hematoma, radiation-induced erythema, and pain at the catheterization site.

Potential device-related adverse events that may occur following device implantation include: stent fracture resulting in recurrent obstruction, endocarditis, embolization or migration of the device, valvular dysfunction (stenosis or regurgitation), paravalvular leak, valvular thrombosis, pulmonary thromboembolism, and hemolysis.


For additional information, please refer to the Instructions for Use provided with the product or call Medtronic at 1-800-328-2518 and/or consult Medtronic's website at [www.medtronic.com](http://www.medtronic.com).

Melody and Ensemble are trademarks of Medtronic, Inc.

**Humanitarian Device.** Authorized by Federal law (USA) for use in patients with a regurgitant or stenotic Right Ventricular Outflow Tract (RVOT) conduit ( $\geq 16$  mm in diameter when originally implanted). The effectiveness of this system for this use has not been demonstrated.



## BVS Cohort A



## CYPHER




Figure 3: Histologic comparison of BVS 1.0 and Cypher stents in porcine model. The neointimal response was comparable between the two implants at 28 and 90 days in terms of neointimal composition and coverage. At later time points, however, the neointimal response to BVS stents was milder.

The ABSORB EXTEND trial is a single-arm study currently enrolling patients throughout Europe, Asia, Canada, and Latin America. The trial will include patients with more complex coronary artery disease than those in the previous ABSORB cohorts.

### Biocorrosible Materials

Corrosion is a design consideration that must be taken into account for any metallic implant. It can lead to premature device failure and can affect biocompatibility by releasing metal ions/particles. While typically a hindrance that must be carefully combated, this property is now being investigated for positive uses. Biocorrosible metallic implants have the mechanical advantages of stainless steel, while also incorporating the benefits of a temporary scaffold like the previously described biodegradable devices.

### Absorbable Magnesium Stent

The absorbable magnesium stent (AMS) was the first metallic bioabsorbable stent to be implanted in a human. The device is laser cut from tubular magnesium WE-43 (Figure 4). Arterial wall coverage is comparable to that of conventional BMS. Initial radial strength is similar to stainless steel stents. It is radiolucent and lacks radio-opaque markers. Absorption is by surface erosion, so strut thickness decreases as the stent is absorbed.

The PROGRESS-AMS trial was a prospective nonrandomized study of 63 patients with simple de novo native coronary artery lesions in whom magnesium stents were implanted. Angiographic results immediately after implantation were similar to those seen with conventional BMS. Radial




Figure 4: The Biotronik absorbable magnesium stent.

support, however, was lost very early, and accordingly there was a high restenosis rate of almost 50% at 4 months.

While the AMS stent is clearly not ideal for use in coronary applications, it may be well suited for pediatric applications. The AMS was successfully implanted in two newborns for emergency off-label uses. Its first use was in a 6 week-old female baby who had been born prematurely at 26 weeks gestation. In this case, the AMS was used to correct an accidental ligation of the left pulmonary artery. At 5 months, after the stent had been completely degraded, left lung perfusion remained adequate. The second pediatric application of the AMS was in a 3 week-old male baby with a postsurgical long-segment recoarctation. This patient also did well with the stent and did not require further intervention until 3 months later.

REGISTER NOW FOR THE 45TH

**Southeast Pediatric Cardiology  
Society Conference**

[www.eply.com/sepcs2012ce](http://www.eply.com/sepcs2012ce) or (404) 785-7744

September 13–15, 2012  
Atlanta, Georgia



## Summary

Because of their use in coronary stents, biodegradable polymers have been developed for use in medical devices. Biodegradable stents and closure devices are in clinical trials. The chemistry and mechanical properties of these materials are well known. It is possible to engineer devices with very predictable degradation times, biology and radial force. Biodegradable materials are likely to replace many of the conventional metals in the current surgical and transcatheter pediatric devices. In general, the ideal material will always need to be non-toxic, non-thrombogenic, and will need to have appropriate strength, elasticity and degradation rate. Because the ideal biodegradable material will need to be tailored from device to device, there is unlikely to ever be one "ideal" biodegradable material. Nonetheless, many challenges remain for the development of devices in the pediatric community. A wide range of potential biodegradable devices can be realized in the pediatric community if the significant biological, regulatory and financial issues in bringing new pediatric biodegradable devices to market can be overcome.

## REFERENCES

1. Serruys PW, Ormiston J, Onuma Y et al (2009) A bioabsorbable everolimus-eluting coronary stent system (absorb): two-year outcomes and results from multiple imaging methods. *Lancet* 373:897-910.
2. Ormiston JA, Serruys PWS (2009) Bioabsorbable coronary stents. *Circ Cardiovasc Intervent* 2:255-260.
3. Kimura T, Abe K, Shizuta S et al (2002) Long-term clinical and angiographic follow-up after coronary stent placement in native coronary arteries. *Circulation* 105:2986-2991.
4. Ratner BD, Hoffman AS, Schoen FJ et al (1996) Biomaterials science: an introduction to materials in medicine. Academic Press, San Diego.
5. Devellian SA, Kladakis SM, Opolski SW, Wright JA (2010) Engineering aspects of metallic and bioabsorbable devices. In: Hijazi ZM, Feldman T, Abdullah Al-Qbandi MH, Sievert H (eds) *Transcatheter closure of ASDs and PFOs: a comprehensive assessment*. Cardiotext Publishing, Minneapolis.
6. Nair LS, Laurencin CT (2006) Polymers as biomaterials for tissue engineering and controlled drug delivery. *Adv Biochem Eng Biotechnol* 102:47-90.
7. Eppley BL, Morales L, Wood R et al (2003) Resorbable PLLA-PGA plate and screw fixation in pediatric craniofacial surgery: clinical experience in 1883 patients. *Pediatric Craniofacial Surgery* 114(4): 850-856.
8. Middleton JC, Tipton AJ (2000) Synthetic biodegradable polymers as orthopedic devices. *Biomaterials* 21:2335-2346.
9. Griffith LG (2000) Polymeric biomaterials. *Acta Materialia* 48(1): 263-277.
10. Athanasiou KA, Agrawal CE, Barber FA, Burkhart SS (1998) Orthopaedic applications for PLA-PGA biodegradable polymers. *Arthrosc:J Arthrosc Relat Surg* 14(7):726-737.
11. Suganuma J, Alexandar H (1993) Biological response of intramedullary bone to poly(L-lactic acid). *J Appl Biomater* 4:13-27.
12. Akin I, Schneider H, Ince H et al (2011) Second- and third-generation drug eluting coronary stents: progress and safety. *Herz* 36:190-197.
13. Stone G, Ellis S, Colombo A et al (2007) Offsetting impact of thrombosis and restenosis on occurrence of death and myocardial

## PEDIATRIC HEART FAILURE/ TRANSPLANT CARDIOLOGIST OPPORTUNITY



The Departments of Pediatrics at the University of Louisville School of Medicine and Kosair Children's Hospital are recruiting for a medical director of heart failure and cardiac transplantation for the Congenital Heart Center at Kosair Children's Hospital in Louisville, Ky.

The primary responsibilities for this position focus on directing and expanding current clinical programs in pediatric heart failure and transplantation to include collaborating with very successful clinical programs in adult heart failure, mechanical assist devices and transplantation. The Kosair Charities Pediatric Heart Research Program at the Cardiovascular Innovation Institute in Louisville and a broad array of basic science research programs at the University of Louisville provide outstanding research infrastructure and collaborative opportunities, with active programs in basic science and translational research involving tissue engineering, stem cells and ventricular assist devices.

An excellent multi-year compensation package is available, commensurate with expertise. Contact Christopher L. Johnsrude, M.D., chief of pediatric cardiology, at [cljohn02@louisville.edu](mailto:cljohn02@louisville.edu) or (502) 852-3876, or Amanda R. Bailey, physician recruitment manager, Norton Physician Services, at (502) 439-5144 or [amanda.bailey@nortonhealthcare.org](mailto:amanda.bailey@nortonhealthcare.org).



KOSAIR  
CHILDREN'S  
HOSPITAL



Kosair Children's Hospital (a part of Norton Healthcare) and the University of Louisville are Affirmative Action, Equal Opportunity, Americans with Disabilities employers, committed to diversity. In that spirit, we seek applications from a broad variety of candidates.



ACHA - 6757 Greene Street, Suite 335 - Philadelphia, PA, 19119  
P: (888) 921-ACHA - F: (215) 849-1261

*A nonprofit organization which seeks to improve the quality of life and extend the lives of congenital heart defect survivors.*

<http://achaheart.org>



- infarction after paclitaxel-eluting and bare metal stent implantation. *Circulation* 115:2842-2847.
14. Serruys PW, Daemen J (2007) Late stent thrombosis: a nuisance in both bare metal and drug-eluting stents. *Circulation* 115:1433-1439.
  15. Costa RA, Lansky AJ, Mintz GS et al (2005) Angiographic results of the first human experience with everolimus-eluting stents of the treatment of coronary lesions (the FUTURE I trial). *Am J Cardiology* 95(1):113-116.
  16. Grube E, Sonoda S, Ikeno F et al (2004) Six- and twelve-month results from first human experience using everolimus-eluting stents with bioabsorbable polymer. *Circulation* 109:2168-2171.
  17. Tomita H, Watanabe K, Yazaki S et al (2003) Stent implantation and subsequent dilatation for pulmonary vein stenosis in pediatric patients: maximizing effectiveness. *Circ J* 67:187-190.
  18. Onuma Y, Serruys PW, Ormiston JA et al (2010) Three-year results of clinical follow-up after a bioresorbable everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB trial. *EuroIntervention* 6(4):447-453.
  19. Serruys PW, Onuma Y, Ormiston JA et al (2010) Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis. *Circulation* 122:2301-2312.
  20. Onuma Y, Serruys PW, Gomez J et al (2011) Comparison of in vivo acute stent recoil between the bioresorbable everolimus-eluting coronary scaffolds (revision 1.0 and 1.1) and the metallic everolimus-eluting stent. *Catheter Cardiovasc Interv* 78:3-12.
  21. Tanimoto S, Serruys PW, Thuesen L et al (2007) Comparison of in vivo acute stent recoil between the bioabsorbable everolimus-eluting coronary stent and the everolimus-eluting cobalt chromium coronary stent. *Catheter Cardiovasc Interv* 70:515-523.
  22. Diletti R, Onuma Y, Farooq V et al (2011) 6-month clinical outcomes following implantation of the bioresorbable everolimus-eluting vascular scaffold in vessels smaller or larger than 2.5 mm. *J Am Coll Cardiol* 58(3):258-264.
  23. Peuster M, Hesse C, Schloo T et al (2006) Long-term biocompatibility of a corrodible peripheral iron stent in the porcine descending aorta. *Biomaterials* 27(28):4955-4962.
  24. Erbel R, Di Mario C, Bartunek J et al (2007) Temporary scaffolding of coronary arteries with bioabsorbable magnesium stents: a prospective non-randomized multicentre trial. *Lancet* 369:1869-1875.
  25. Zartner P, Cesnjevar R, Singer H, Weyand M (2005) First successful implantation of a biodegradable metal stent into the left pulmonary artery of a preterm baby. *Catheter Cardiovasc Interv* 66:590-594.
  26. Schranz D, Zartner P, Michel-Behnke I, Akinturk H (2006) Bioabsorbable metal stents for percutaneous treatment of critical recoarctation of the aorta in a newborn. *Catheter Cardiovasc Interv* 67:671-673.
  27. Luo JC, Chen W, Chen XH et al (2011) A multi-step method for preparation of porcine small intestinal submucosa (SIS). *Biomaterials* 32:706-713.
  28. Robotin-Johnson MC, Swanson PE, Johnson DC et al (1998) An experimental model of small intestinal submucosa as a growing vascular graft. *J Thorac Cardiovasc Surg* 116(5):805-811.
  29. Hata H, Bar A, Dorfman S et al (2010) Engineering a novel three-dimensional contractile myocardial patch with cell sheets and decellularised matrix. *Eur J Cardiothorac Surg* 38(4):450-455.
  30. Crapo PM, Wang Y (2010) Small intestinal submucosa gel as a potential scaffolding material for cardiac tissue engineering. *Acta Biomater* 6(6):2091-2096.
  31. Okada M, Payne TR, Oshima H et al (2010) Differential efficacy of gels derived from small intestinal submucosa as an injectible biomaterial for myocardial infarct repair. *Biomaterials* 31(30):7678-7683.
  32. Morgan G, Lee KJ, Chaturvedi R, Benson L (2010) A biodegradable device (BioSTAR) for atrial septal defect closure in children. *Catheter Cardiovasc Interv* 76(2):241-245.
  33. Hoehn R, Hesse C, Ince H, Peuster M (2010) First experience with the Biostar-device for various applications in pediatric patients with congenital heart disease. *Cath Cardiovasc Interv* 75:72-77.
  34. Majunke N, Sievert H (2007) ASD/PFO devices: what is in the pipeline? *J Intervent Cardiol* 20:517-523.
  35. Pavcnik D, Takulve K, Uchida BT et al (2010) Biodisk: a new device for closure

## Pediatric Cardiology Practice for Sale

Well-established pediatric cardiology practice of 25 years in gulf region, is for sale. The physician/owner is planning to retire soon. Practice is continuing to grow with great potential to expand in multiples. Office is fully equipped with ECG, Echocardiogram, holter and stress test.

Collections have been consistently over \$500K, low overhead. Well-established and wide-based referral system is already in place, with great potential to grow in peripheral area. There are 2 NICU in the area. Invasive and interventional cath labs are available to pursue interest. 2 groups of perinatologists, all pediatric subspecialists including pediatric surgeon and intensivists in the area as support structure is in place.

Culturally rich area to raise family and great year round recreational facility, makes this a very attractive place to live. Area is economically very strong and growing with wide diversity. Great and diverse gastronomy is appealing to any palate!

Owner will stay on for some time to introduce new physician to referring physicians.

**Please contact**

**Practice@CCT.bz**

**SPECIALTY  
REVIEW IN** **Pediatric  
Cardiology**  
**SEPTEMBER 10-14, 2012 • CHICAGO**

**A BOARD REVIEW COURSE PRESENTED BY  
American Academy of Pediatrics Section on Cardiology & Cardiac Surgery  
— in collaboration with —  
Society of Pediatric Cardiology Training Program Directors**

*Discounts for early registration and AAP members available.*

**[www.aap.org/sections/cardiology/pediatric\\_cardiology/2012](http://www.aap.org/sections/cardiology/pediatric_cardiology/2012)**



of patent foramen ovale: a feasibility study in swine. Catheter Cardiovasc Interv 75:861-867.

36. Ruiz CE, Iemura M, Medie S et al (2005) Transcatheter placement of a low-profile biodegradable pulmonary valve made of small intestinal submucosa: a long-term study in a swine model. J Thorac Cardiovasc Surg 130(2):477-484.

**CCT**

### Biographical Sketch of Principal Author

Daniel S. Levi, MD is an Interventional Pediatric Cardiologist who has served on the UCLA School of Medicine faculty since 2003. His primary clinical role involves the use of catheters and devices to help children with congenital heart disease. He is internationally known for his laboratory and clinical research. He is also the director of the adult congenital interventional catheterization program and director of the fellowship program in pediatric cardiology, and is a member of the pediatric heart transplantation team.

Dr. Levi earned his B.S. in Biology from Stanford (1992) and his M.D. from UCSF (1997). He was in the Medical Scientist Training Program at UCSF from 1992-1995. After Pediatrics internship and residency were completed at UCSF, Dr Levi completed his pediatric cardiology fellowship and pediatric interventional cardiology subspecialization at UCLA. He is board certified in Pediatric Cardiology by the American Academy of Pediatrics, he is the recipient of the Gerd Hausdorf Pediatric Research Award and is director of the Congenital Program of the Society for Cardiac Angiography and Interventions (SCAI) annual program. His laboratory research centers on the development of novel pediatric stents and other devices made from nano-synthesized "smart" materials such as thin film nitinol. Dr. Levi is been the recipient of grants from the National Institute of Health (NIH), National Science Foundation (NSF), the American Heart Association (AHA), the Paige Foundation and multiple other foundations and agencies.



### Corresponding Author

*Daniel S. Levi, MD  
Director, Diagnostic and Interventional Catheterization Program  
Associate Professor  
Division of Pediatric Cardiology  
Mattel Children's Hospital  
University of California, Los Angeles  
B2-427 MDCC  
10833 Le Conte Avenue  
Los Angeles, CA 90095-1743 USA  
(310) 206-3478*

*dlevi@mednet.ucla.edu*



*Andrew L. Cheng, MD  
Department of Pediatrics  
Mattel Children's Hospital  
University of California, Los Angeles  
B2-427 MDCC  
10833 Le Conte Avenue  
Los Angeles, CA 90095-1743 USA  
(310) 206-3478*

*acheng@mednet.ucla.edu*

### Coming in the August issue

FDA Clearance of Cardiac Devices for Children: A Primer and Call to Action  
By Robert H. Beekman, III, MD



**The Children's Hospital of Illinois and University of Illinois College of Medicine at OSF Saint Francis Medical Center are Seeking Pediatric Cardiologists in Peoria and Rockford, Illinois**

**Peoria** - The new pediatric cardiologist will join a well-established team of 7 pediatric Cardiologists with 30 plus years of success in the region. In addition to general pediatric cardiology, opportunities are focused on those interested in echocardiography, fetal echocardiography, and adult congenital heart disease. Professional components include in-patient rotation coverage, general cardiology clinic coverage and in-patient/out-patient echocardiography. Scholarly and research interests are highly desirable, along with experience in teaching medical students and residents. The candidate must be board-certified or board-eligible in pediatric cardiology and will report to the Medical Director, Pediatric Cardiology.

**Rockford** - A BC/BE noninvasive pediatric cardiologist is desired to join 3 well established pediatric cardiologists in the Rockford branch of the Congenital Heart Center (CHC) system. The practice has been a stable source of quality pediatric cardiology care in the community for more than 20 years. The candidate should be skilled in all facets of echocardiography. Skills in fetal cardiology are desirable. The qualified individual will be part of the CHC which includes an additional 8 cardiologists at the Peoria campus. There is a direct clinical and academic relationship between the two groups.

The University of Illinois is an Affirmative Action/Equal Opportunity employer.

**Stacey Morin, OSF Pediatric Cardiology  
CHOI**

**Ph: 309-683-8354 or**

**800-232-3129 press 8; Fax: 309-683-8353**

**E-mail: [stacey.e.morin@osfhealthcare.org](mailto:stacey.e.morin@osfhealthcare.org)**

**Website: [www.childrenshospitalofil.org](http://www.childrenshospitalofil.org)**



**PICS-AICS**

Pediatric and Adult Interventional Cardiac Symposium

**MIAMI**

**LOEWS MIAMI BEACH HOTEL  
JANUARY 19-22, 2013**



[www.picsymposium.com](http://www.picsymposium.com)

# Highlights of Inaugural Breakout Session of PICES (Pediatric/Congenital Interventional Cardiology Early-Career Society) at SCAI's Annual Meeting

By Brent M. Gordon, MD

The Pediatric/Congenital Interventional Cardiology Early-Career Society (PICES) held its inaugural breakout sessions at both the PICS/AICS and SCAI conferences in 2012. PICES was established in July of 2011, and is currently a task force under the umbrella of the Congenital Heart Disease council of SCAI. The group was established to support and advance the careers of young interventionalists in structural heart disease. The PICES group has several goals including: clinical education, multi-center research collaboration, improving transcatheter treatment of congenital heart disease in developing countries, and creation of a social network. The PICES executive board is composed of president Daniel H. Gruenstein, MD, from University of Minnesota, Amplatz Children's Hospital; clinical chair Brent M. Gordon, MD, from Loma Linda University Children's Hospital; research chair Michael A. Bingler, MD, from Children's Mercy Hospital, Kansas City; and secretary John S. Lozier, MD, from Pediatric Cardiology PC, Mercy Medical Center, Des Moines, Iowa.

The breakout session at PICS began with a welcome from Dan Gruenstein, followed by a guest lecture from Henri Justino, MD, from Texas Children's Hospital entitled, "Creating a Career Niche-Revascularization of Thrombosed Vasculature in Pediatric Patients." Dr. Justino profiled several truly remarkable outcomes in neonates and children with life-threatening vascular thromboses and discussed several modalities available to treat this difficult subset of patients. The talk concluded with suggestions and philosophies that young interventionalists may utilize to help establish a career niche for themselves. This was followed by case presentations from Bryan Goldstein, MD, and Nathaniel Taggart, MD. Dr. Goldstein discussed a case of severe aortic coarctation with associated aneurysmal involvement of the left subclavian artery that was treated with a covered CP stent, while Dr. Taggart presented an example of transcatheter Fontan completion. The cases generated healthy discussion from the audience and lent themselves to numerous teaching points.

---

***"The PICES group has several goals including: clinical education, multi-center research collaboration, improving transcatheter treatment of congenital heart disease in developing countries, and creation of a social network."***

---

The PICS meeting also featured the inaugural selection of the Young Leadership Program for early career interventionalists. Christopher Petit, MD, from Texas Children's Hospital and a PICES member, was selected as the initial recipient. Dr. Petit was designated a faculty member for the meeting and had the opportunity to chair several sessions throughout the meeting while participating with the other faculty. PICES was very involved in creating the Young Leader Program and congratulates Dr. Petit on all of his accomplishments.

The PICES group also had a significant presence at SCAI that culminated in a breakout session on Friday afternoon. The session began with a talk by Lynn Peng, MD, from Lucille Packard Children's Hospital at Stanford University on the Emerging Leadership Mentoring (ELM) Program. The ELM program, of which Dr. Peng is currently the only pediatric interventional representative, was created by SCAI to pair young interventionalists with senior mentors, with the ultimate goal of training younger faculty to become the leaders of tomorrow in the treatment of structural heart disease. The next series of ELM applications will be due in the fall of 2012. Please see the SCAI website for further information.

The breakout session continued with several interesting case presentations. Jeffery Zampi,

MD from University of Michigan discussed transcatheter Fontan fenestration creation, Luke Lamers, MD from Phoenix Children's Hospital showed a coronary artery fistula case with some bonus operator chest pain, and Michael Bingler, MD discussed the utility of balloon angioplasty in the treatment of discrete subaortic membrane. After a close vote, Dr. Lamer's case was deemed the best presentation and he received the inaugural PICES case presentation award, which he will watch over until the next meeting. Congratulations Dr. Lamers for a job well done.

The PICES membership is now approaching 80 people with representatives from the United States and several other countries around the world. We plan to have a link to our website operational within the next few months and are excited to initiate some multi-center studies before the end of summer. The next formal meeting will be in January 2013 at PICS in Miami. Nominations for future board members will be accepted at that time with elections to follow at SCAI in Orlando. For further information or to be added to the PICES list-serve please contact John Lozier at: [john.lozier@gmail.com](mailto:john.lozier@gmail.com).

CCT



Brent M. Gordon, MD  
Assistant Professor, Division of Pediatric Cardiology  
Loma Linda University Medical Center  
11234 Anderson St., MC-4433  
Loma Linda, CA 92354-0200 USA  
Phone (909) 558-4711  
Fax (909) 558-0311  
Pager (909) 216-0361  
[brgordon@llu.edu](mailto:brgordon@llu.edu)



11615 Hesby Street  
N. Hollywood, CA 91601  
Tel: 818.754.0312 Fax: 818.754.0842  
[www.campdelcorzan.org](http://www.campdelcorzan.org)

# Medical News, Products and Information

## The Children's Cardiomyopathy Foundation's Grant Announcement

The Children's Cardiomyopathy Foundation (CCF) is pleased to announce the availability of one-year research grants for studies focused on pediatric cardiomyopathy. The purpose of CCF's Annual Research Grant Program is to advance knowledge of the basic mechanism of the disease and to develop more accurate diagnostic methods and improved therapies for children affected with cardiomyopathy. Please visit CCF's website [www.childrenscardiomyopathy.org](http://www.childrenscardiomyopathy.org) (click on Research/Grants & Awards) for guidelines and to view past grant awards.

### Request for Research Applications on Pediatric Cardiomyopathy

Dilated, Hypertrophic, Restrictive, Left Ventricular Non-Compaction or Arrhythmogenic Right Ventricular Cardiomyopathy.

**Opportunity:** The Children's Cardiomyopathy Foundation (CCF) is inviting investigator-initiated research proposals for innovative basic, clinical, population, or translational studies related to the cause, diagnosis, or treatment of primary cardiomyopathy in children under the age of 18 years. CCF's grant program is designed to provide seed funding to investigators for the testing of initial hypotheses and collecting of preliminary data to help secure long-term funding by the NIH and/or other major granting institutions.

**Eligibility:** Principal investigator must hold an MD, PhD or equivalent degree and reside in the United States or Canada. The investigator must have a faculty appointment at an accredited US or Canadian institution and have the proven ability to pursue independent research as evidenced in publications in peer-review journals.

**Funding:** Funding is available in the range of US\$25,000 to US\$50,000 for one year of total direct costs. Following the completion of the proposed study, a second year of funding may be an option for relevant study extensions.

**Application Process:** CCF grant guidelines and application forms are downloadable off the website at [www.childrenscardiomyopathy.org/site/grants.php](http://www.childrenscardiomyopathy.org/site/grants.php). The 2012 deadline for application submission is Friday, September 7, 2012 with final award decisions to be made by January 2013.

**Selection Process:** Grant award decisions are made through a careful peer-review process led by CCF's Medical Advisors and reviewed by CCF's Board of Directors. Scientific excellence and relevance to primary forms of pediatric cardiomyopathy are the main criteria for selecting research projects to support.

**Contact:** Lisa Yue, President, Children's Cardiomyopathy Foundation; 866-808-CURE ext. 901 or [lyue@childrenscardiomyopathy.org](mailto:lyue@childrenscardiomyopathy.org).

## ACC President Comments on Congress's Vote Passing FDA User Fee Bill

"The American College of Cardiology supports Congress's decision to reauthorize FDA's user fees for devices and prescription drugs. Appropriate funding allows the FDA to provide oversight and to review and approve new treatments in a timely manner," said ACC President William Zoghbi, MD, FACC in a statement.



## Transplant Cardiologist Assistant or Associate Professor (In Residence, Adjunct, or Clinical)

THE UNIVERSITY OF CALIFORNIA, SAN DIEGO, DEPARTMENT OF PEDIATRICS (<http://www-pediatrics.ucsd.edu>) AND CHILDREN'S SPECIALISTS OF SAN DIEGO (<http://childrensspecialists.com>) are committed to academic excellence and diversity within the faculty, staff, and student body and are jointly recruiting a Medical Director of Cardiac Transplantation for the unified Division of Pediatric Cardiology at Rady Children's Hospital, San Diego. This 220-bed facility serves as a major regional tertiary care hospital for children and is the major teaching facility for the Department of Pediatrics of the UCSD School of Medicine.

The Director position is a unique opportunity to develop an exceptional Cardiac Transplantation Program in San Diego. The successful candidate must have training and experience in a UNOS certified pediatric cardiac transplant center and should possess the qualifications for academic appointment at the rank of Assistant or Associate Professor. The academic series will be determined based on the background and qualifications of the successful candidates. Candidates must be Board Certified in Pediatric Cardiology and licensed or licensable to practice medicine in the State of California. This appointment will require demonstrated administrative capabilities, excellent skills in clinical care and teaching, and research accomplishment.

The Division provides a full range of Pediatric Cardiology services. It currently has six pediatric cardiologists, two cardiothoracic surgeons, and an ACGME approved fellowship program. The Division supports a program with approximately 400 surgical procedures yearly. Extensive opportunities to perform clinical, epidemiologic or basic science research exist at UCSD and Children's Hospital, San Diego.

Salary commensurate with qualifications and based on University of California pay scales.

Applications received by July 1, 2011 or until the position is filled, will receive full consideration.

**Please send Curriculum Vitae, the names and e-mail addresses for three references, and a personal statement summarizing your demonstrable commitment to promoting and enhancing diversity and equality, or your potential to make contributions in the field.**

Please apply to UCSD's application collection system, Recruit at:  
<https://apol-recruit.ucsd.edu/apply> (preferred method)

or by e-mail to:  
John Moore, M.D. - [jmoore@rchsd.org](mailto:jmoore@rchsd.org)

or by mail to:  
3020 Children's Way, MC 5004  
San Diego, CA 92123

*UCSD is an Affirmative Action/Equal Opportunity Employer with a strong institutional commitment to excellence through diversity.*

"Innovative treatments have played a pivotal role in reducing deaths due to cardiovascular disease in recent decades. It is important to support a system that encourages the development of new medications and devices. The College commends Congress for taking steps to improve post-market surveillance of medical devices and increase the use of data registries to improve patient care and device safety. The agreement is excellent for patient health, the future of medical science and continued advances in the field of cardiology."





## Pediatric Cardiac Critical Care Physician Chicago Area

Advocate Medical Group (AMG), a physician-led multi-specialty team of over 900 physicians, seeks an experienced board certified/board eligible Pediatric Cardiac Critical Care specialist to join The Heart Institute for Children at Advocate Hope Children's Hospital. Located in suburban Chicago this unique, thriving, dynamic clinical practice includes 16 Pediatric Cardiologists.

Position includes the opportunity to educate residents and fellows from multiple area institutions. The program has over 8000 clinic visits per year, 4500 on-site echocardiograms, 300 cardiac catheterizations, and 350-450 surgeries/year at our main campus alone. Our surgical group averages 700+ surgeries per year at multiple sites. Our outcomes are among the best in the nation. We have an accredited cardiology fellowship program with 6 fellows. We have a dedicated 9 bed Pediatric Surgical Heart Unit, an additional 15 bed Pediatric Intensive Care Unit, and a 4 bed step down unit.

Candidates must be BC/BE in Pediatric Cardiology or Pediatric Critical Care. Board Certification in both subspecialties is preferred but not required. This is an outstanding opportunity for the right individual who is interested in both cardiology and critical care. Additional training can be provided on-site dependent upon needs (with consideration for a fourth year training period for recent graduates). Numerous opportunities for research and professional growth exist. Excellent benefit package is offered.

It goes without saying that Chicago is indeed a wonderful place to live. It is a beautiful city that boasts a diverse cultural and historic background.

**Interested candidates should send their resume to:**

Donna C. Kutka, R.N., M.S.  
Director, Physician Recruitment  
708.684.5009  
[donna.kutka@advocatehealth.com](mailto:donna.kutka@advocatehealth.com)

Andrew Van Bergen, MD  
Director, Pediatric Cardiac Critical Care  
The Heart Institute for Children  
Advocate Hope Children's Hospital

The American College of Cardiology is transforming cardiovascular care and improving heart health through continuous quality improvement, patient-centered care, payment innovation and professionalism. The College is a 40,000-member nonprofit medical society comprised of physicians, surgeons, nurses, physician assistants, pharmacists and practice managers, and bestows credentials upon cardiovascular specialists who meet its stringent qualifications. The College is a leader in the formulation of health policy, standards and guidelines, and is a staunch supporter of cardiovascular research. The ACC provides professional education and operates national registries for the measurement and improvement of quality care. More information about the association is available online at [www.cardiosource.org/ACC](http://www.cardiosource.org/ACC).

### The China California Heart Watch Looking for Participants for Several Internships

The China California Heart Watch is a not-for-profit public charity whose missions include medical research, teaching and clinical care in rural Yunnan Province, China. They invite students, particularly those interested in future careers in medicine, public health or related fields to participate in one of several internships this year. These internships involve first-hand exposure to medical problems – particularly cardiovascular problems – and care in impoverished communities, where access to high-quality medical services is very limited.

**Objective:** The objective of the internship program is to create awareness of the problems of healthcare in rural China, and encourage students to pursue a career in public health and/or medicine focused on the underserved in developing countries.

**Students:** China Cal will have three internship programs for the remainder of 2012. Each is open to 5-15 students. Candidates will be interviewed to determine suitability. To intern at China Cal, you must have an interest in pursuing a career involving public health or health-related care in underserved populations. Some knowledge of Mandarin is desirable, although this is not a strict requirement.

August-December 2012 upcoming Internship dates: August 4<sup>th</sup> – 26<sup>th</sup>; September 1<sup>st</sup> – 23<sup>rd</sup>; and December 14<sup>th</sup> – 30<sup>th</sup>.

**Programs:** Upon arrival in Yunnan (Kunming or Dali), students will undergo three days of training and certification. Students will learn about how to assist in a program focuses on screening and treatment of adults and school children living in rural towns, who have high blood pressure and heart disease. We then travel to surrounding areas to begin clinics among rural populations. Interns will travel and work alongside with faculty members from Kunming and Dali Universities, as well as receiving training from Dr. Robert C. Detrano, MD, PhD, Professor of Radiological Sciences at the University of California at Irvine and a board-certified cardiologist. Interns will also have the opportunity to help conduct a clinical research program while staying in villages in Yunnan. To read experiences of recent interns, please visit: [www.chinacal.org](http://www.chinacal.org).

**Logistics:** Students will travel to Yunnan Province, where several China Cal staff will meet the students at the airport. China Cal will arrange all accommodations, as well as any local travel (by bus, train or air as needed). Students will be living in hotels, community centers and, occasionally while in remote areas, the homes of farmers.



**Archiving Working Group**  
**International Society for Nomenclature of**  
**Paediatric and Congenital Heart Disease**  
[ipccc-awg.net](http://ipccc-awg.net)

Students are required to cover the cost of all travel expenses to, from and within China, as well as room and board. China Cal also requests a tax-free donation of US\$2000 for all summer programs or US\$1500 for the December program. This donation helps fund China Cal's charitable activities, including training village doctors, acquiring medical equipment, and conducting hypertension research. Foreigners require a valid visa to enter China. This must be organized through agencies or the Chinese consulate/embassy in the student's home country.

**Health and Safety:** Yunnan Province is a relatively safe place for foreign visitors. Students will be advised regarding caution and care for their belongings and documents. Health risks are relatively few. However, as visitors sometimes suffer from gastroenteritis, China Cal doctors will provide prophylactic education, and medications will be on-hand if needed.

For more information about China Cal's programs, visit their website at [www.chinacal.org](http://www.chinacal.org) or contact Mr. Roy Chan at [rychan@uci.edu](mailto:rychan@uci.edu).

### **Women Undergoing TAVI Using the Medtronic CoreValve® System Have Similar Survival Benefit as Men**

Rigorous Trial Design and Monitoring Provides New Insight to Outcomes for Men and Women with Aortic Stenosis

PARIS--(BUSINESS WIRE)--May. 17, 2012-- Medtronic, Inc. (NYSE: MDT) has announced new results from the Medtronic CoreValve ADVANCE Study, which found that women and men benefitted similarly from the Medtronic CoreValve® System. The study, presented at EuroPCR 2012, evaluated patients who were at high-risk for surgical aortic valve replacement. The Medtronic CoreValve System is currently limited to investigational use in the United States.

The gender analysis, a secondary-endpoint evaluation in the real-world CoreValve ADVANCE Study, found that survival rates were nearly identical between genders, with no statistical differences in 30-day and 6-month all-cause mortality, cardiovascular mortality or the 30-day MACCE endpoint (Major Adverse Cardiac & Cerebrovascular Events, a composite of all-cause mortality, myocardial infarction, emergent cardiac surgery or percutaneous re-intervention, and stroke).

Overall, patients experienced low 30-day stroke rates (2.9%), with the combined stroke rates of major and minor strokes being very low (major 1.2%, and minor 1.7%). However, female patients experienced a statistically higher rate of strokes (4.4% vs. 1.4%; p-value <0.01), major vascular complications (14.1% vs. 7.1%; p-value <0.01) and major bleeding (5.0% vs. 3.1%; p-value <0.01). For minor stroke between genders, and for major strokes between genders, differences were not significant, though there was a trend for women to have more minor strokes than men.

"This study is an important contribution to the growing base of research on TAVI, and sheds light on the unique needs for managing severe aortic stenosis in women," said Patrizia Presbitero, MD, Director of Interventional Cardiology at Hospital Humanitas Rozzano in Milan and an investigator in the CoreValve ADVANCE Study, and a professional development co-chair and member of the Leadership Council of WIN (Women in Innovations/Society for Cardiovascular Angiography and Interventions, SCAI). "We need to know more about gender differences to effectively treat patients with heart disease in a more specific way, taking into account those differences that can affect treatment."

Women and men benefitted similarly from the CoreValve System even though women (51% of patients) and men (49% of patients) had different risk profiles. Specifically, at the time of enrollment, women as compared to men were:

- Older than males (82.2 years vs. 79.9 years; p-value <0.001);
- Had higher average gradients (47.6 vs. 43.5 mmHg; p-value <0.001) and peak gradients (79.0 vs. 72.5 mmHg; p-value <0.001), a measure of blood flow across the valve;

## **Pediatric Cardiology Division Chief**

The Department of Pediatrics at the Wake Forest University School of Medicine (WFUSM) in Winston Salem, North Carolina, is recruiting a full-time section head (chief) for the division of Pediatric Cardiology. The ideal candidate will be a board certified cardiologist with training and experience in providing leadership, as well as clinical, academic and service excellence. The candidate should have already achieved the rank of associate or full professor, or be qualified for promotion to the rank of associate professor in the department of Pediatrics. In addition to proven leadership abilities, a strong record of research or academic success is required.

The Children's Heart Program at Brenner Children's Hospital functions as a service-line enterprise with support from the hospital administration. The chief of cardiology will be responsible for providing clinical oversight and supporting the academic growth of the current faculty of eight and will also function in collaboration with the director of the Children's Heart Program (one of the two CT surgeons, who is ABTS certified in congenital heart surgery), the vice-president of Brenner Children's Hospital, and the chair of the department of Pediatrics, to formulate the strategic vision for growth of the program. This is a major leadership position for our Children's Hospital and consequently, the successful candidate will receive appropriate support, including an opportunity to recruit other essential team members as needed and develop required programs. We want this important recruit to be successful in helping us achieve our strategic goals of becoming the recognized center of excellence for congenital heart care in Western North Carolina, as well as their own goals to be recognized as a successful leader in academic pediatric cardiology. An interest in and track record of teaching medical students, residents and fellows is required. We are in the process of submitting our PIF for a pediatric cardiology fellowship.

Winston Salem offers a lifestyle that is tough to beat...a short commute, low cost of living, excellent school choices, diverse cultural amenities...a wonderful place to live and raise a family. The city is home to Wake Forest University, one of the country's top academic institutions. We are conveniently located close to beautiful recreational lakes, just over an hour to the NC mountains and three to four hours to the Carolina beaches.

Wake Forest University Baptist Medical Center is an affirmative action and equal opportunity employer with a strong commitment to achieving diversity among its faculty and staff.

### **Interested candidates should contact:**

Bill Selvey  
WilliamLaine, Inc.  
direct 404-495-9411, toll free 877-231-8379  
[bselvey@williamlaine.com](mailto:bselvey@williamlaine.com)



- Had less coronary artery disease (46% vs. 70%; p-value <0.001); and
- Were prescribed fewer cardiovascular medications, including cholesterol-lowering medications (p-value 0.002) and statins (p-value 0.013).

"The robust ADVANCE trial provides a compelling discovery that the CoreValve System is an excellent therapeutic option for both men and women, and it helps us begin to consider how men and women



## Pediatric Cardiologists

The Division of Pediatric Cardiology at the University of Utah School of Medicine and based at Primary Children's Medical Center is recruiting board eligible/board certified pediatric cardiologists with major interests in 1) Heart Transplant/Heart Failure and 2) Adult Congenital Heart Disease. The Pediatric Cardiologists will join a 25-member division and established Heart Transplant and Adult Congenital Heart Disease Programs. There will be protected time and mentoring available within the Division for clinical research. The Division has a very active clinical research program and is one of the participating centers in the Pediatric Heart Disease Clinical Research Network funded by the NIH.

The successful candidates will receive a faculty appointment at the University of Utah on the clinical or tenure track. Rank will be dependent on qualifications. The University of Utah offers an excellent benefits package that includes 20.2% retirement contributions that vest immediately, and excellent health care choices. Salt Lake City is a diverse major metropolitan area with outstanding restaurants, arts and music. Recreation is unparalleled with 6 ski resorts within 30 minutes and 5 national parks within an easy 4 hour drive. It is serviced by a convenient international airport with direct flights to most major cities.

To read more about each opportunity and to apply, please go to:

### Heart Transplant/Heart Failure Position

<http://utah.peopleadmin.com/postings/13074>

### Adult Congenital Heart Disease Position

<http://utah.peopleadmin.com/postings/8177>

For additional information, please contact Lloyd Y. Tani, MD:

[lloyd.tani@imail.org](mailto:lloyd.tani@imail.org).

*The University of Utah is an EO/AA employer and educator. Minorities, women, and persons with disabilities are strongly encouraged to apply. Veterans preference. Reasonable accommodations provided. For additional information: <http://www.regulations.utah.edu/humanResources/5-106.html>.*

*The University of Utah Health Sciences Center is a patient focused center distinguished by collaboration, excellence, leadership, and respect. We value candidates who are committed to fostering and furthering the culture of compassion, collaboration, innovation, accountability, diversity, integrity, quality, and trust that is integral to the mission of the University of Utah Health Sciences Center.*



present differently prior to implant and might be managed accordingly," said Axel Linke, MD, Professor of Medicine at Universitat Leipzig Herzzentrum in Leipzig, Germany and principal investigator of the ADVANCE clinical trial. "An important next step will be to further evaluate why stroke events were more common for women, including the possible role of medications which were prescribed less frequently for women in this study."

The ADVANCE study is one of the largest multicenter transcatheter aortic valve implantation (TAVI) trials to date, with 1,015 patients consecutively treated at 44 experienced TAVI centers in 12 countries. Clinical endpoints were calculated according to Valve Academic Research Consortium (VARC) standardized definitions. All data were independently monitored, all adverse events related to the primary endpoints were adjudicated by an independent Clinical Events Committee (CEC) consisting of experienced cardiac surgeons and interventional cardiologists, and all cerebrovascular events (including stroke and other events) were adjudicated by an independent neurologist using neuroimaging and systematic NIH Stroke Scale assessments.

The Medtronic CoreValve System received CE (Conformite Europeenne) Mark in 2007 for the treatment of patients deemed at high or extreme risk for surgery. Since then, it has been implanted in more than 27,000 people in more than 50 countries outside the US. The CoreValve System is available in three sizes (26mm, 29mm and 31mm), and is the only transcatheter aortic valve implantation system approved for direct aortic or subclavian access. For more information visit Medtronic, Inc. at [www.medtronic.com](http://www.medtronic.com).

Worldwide, approximately 300,000 people have been diagnosed with symptomatic, severe aortic stenosis, and approximately one-third of these patients are deemed at too high a risk for open-heart surgery (*Decision-making in elderly patients with severe aortic stenosis: why are so many denied surgery? Bernard lung et al. Eur Heart J (December 2005) 26(24): 2714-2720.*)

### New Column Starts Next Month

This special column will be published bimonthly in *Congenital Cardiology Today* with contributors and images from the *Archiving Working Group of the International Society for Nomenclature of Paediatric and Congenital Heart Disease*.

## CONGENITAL CARDIOLOGY TODAY

© 2012 by Congenital Cardiology Today (ISSN 1554-7787-print; ISSN 1554-0499-online). Published monthly. All rights reserved.

**Corporate Offices:** 8100 Leaward Way, Nehalem, OR 97131 USA

**Mailing Address:** PO Box 444, Manzanita, OR 97130 USA

Tel: +1.301.279.2005; Fax: +1.240.465.0692

### Publishing Management:

- Tony Carlson, Founder, President & Sr. Editor - [TCarlsonmd@gmail.com](mailto:TCarlsonmd@gmail.com)
- Richard Koulbanis, Group Publisher & Editor-in-Chief - [RichardK@CCT.bz](mailto:RichardK@CCT.bz)
- John W. Moore, MD, MPH, Medical Editor - [JMoore@RCHSD.org](mailto:JMoore@RCHSD.org)
- Virginia Dematatis, Assistant Editor
- Caryl Cornell, Assistant Editor
- Loraine Watts, Assistant Editor
- Chris Carlson, Web Manager
- William Flanagan, Strategic Analyst
- Rob Hudgins, Designer/Special Projects

**Editorial Board:** Teiji Akagi, MD; Zohair Al Halees, MD; Mazeni Alwi, MD; Felix Berger, MD; Fadi Bitar, MD; Jacek Bialkowski, MD; Philipp Bonhoeffer, MD; Mario Carminati, MD; Anthony C. Chang, MD, MBA; John P. Cheatham, MD; Bharat Dalvi, MD, MBBS, DM; Horacio Faella, MD; Yun-Ching Fu, MD; Felipe Heusser, MD; Ziyad M. Hijazi, MD, MPH; Ralf Holzer, MD; Marshall Jacobs, MD; R. Krishna Kumar, MD, DM, MBBS; John Lamberti, MD; Gerald Ross Marx, MD; Tarek S. Momenah, MBBS, DCH; Toshio Nakanishi, MD, PhD; Carlos A. C. Pedra, MD; Daniel Penny, MD, PhD; James C. Perry, MD; P. Syamasundar Rao, MD; Shakeel A. Qureshi, MD; Andrew Redington, MD; Carlos E. Ruiz, MD, PhD; Girish S. Shirali, MD; Horst Sievert, MD; Hideshi Tomita, MD; Gil Wernovsky, MD; Zhuoming Xu, MD, PhD; William C. L. Yip, MD; Carlos Zabal, MD

*Statements or opinions expressed in Congenital Cardiology Today reflect the views of the authors and sponsors, and are not necessarily the views of Congenital Cardiology Today.*





# Watch over 300 Live Case Videos, Presentations and Workshops Online from Leading Congenital and Structural Medical Meetings from Around the World - [www.CHDVideo.com](http://www.CHDVideo.com)



- Transseptal Access Workshop from Cook Medical
- Workshop: Past Present and Future of Pediatric Interventions Cardiology - St. Jude & AGA Mmedical
- Symposium on Prevention of Stroke Clinical Trials at the Heart of the Matter - WL Gore Medical
- Imaging in Congenital & Structural Cardiovascular Interventional Therapies
- Morphology of The Atrial Septum
- Morphology of The Ventricular Septum
- Pre-Selection of Patients of Pulmonic Valve Implantation and Post-Procedural Follow-up
- Echo Paravalvular Leakage (PVL)
- ICE vs TEE ASD Closure in Children - PRO & CON ICE
- 3D Rotational Angiography - Why Every Cath Lab Should Have This Modality
- PICS Doorway to the Past - Gateway to the Future
- Follow-up From PICS Live Cases 2010 Presentation
- Intended Intervention - Transcatheter TV Implantation - *Live Case*
- Intended Intervention - LAA Closure Using Amplatzer Cardiac Plug Under GA & Real Time 3D
- Provided Intervention - LPA Stenting / Implantation of a Sapien Valve
- Intended Intervention - PV Implantation
- Intended Intervention - COA Stent Using Atrium Advanta V12 Covered Stent - *Live Case*
- Intended Intervention - ASD Closure - *Live Case*
- Intended Intervention - Transcatheter VSD Device Closure - *Live Case*
- Intended Intervention - COA Stenting Using Premounted Advanta V12 Covered Sten - *Live Case*
- Stunning Revelation - The Medical System is Changing - What Can You Do To Show Patients That Your Practice Does It Right? Patient Perspective
- Percutaneous Paravalvular Leak Closure Outcomes
- Intensive Management of Critically Ill Infants Undergoing Catheterization
- Off Label Device Usage - Careful!
- Evolving Hybrid Programs Communications is the Key
- Anti-Coagulation in Pediatric Interventions - Evidence Please! Are we Flying Blind?
- Shaping Your Structural Heart Interventional Career: How Do I Get the Necessary Training and Start a Program?
- Closure of Post-Infarct VSDs Limitations & Solutions
- Percutaneous Interventions During Pregnancy
- Percutaneous PVL Closure Techniques & Outcomes
- Percutaneous Therapy for MR
- Update on Percutaneous Aortic Valve Replacement: Time to Open the Flood Gates?
- 2011 PICS/AICS Achievement Award Presented To Horst Sievert, MD.
- The Cases I Learn The Most From
- If I was Starting Now I Would... Contemplating the Question.
- 10 Tips for the Trainee
- The Perfect CV
- Why I Left The Cath Lab
- Intended Intervention Occlude Right High Flow Superior Segment PAVM
- Intended Intervention Edwards Sapien XT Transcatheter Heart Valve - 3D Guidance - *Live Case*
- Closure of the Silent PDA - Indicated or Not
- Transcatheter Tricuspid Valve Replacement
- Recommendations For Device Closure of MVSDs
- Intended Intervention Diagnostic Angio/First Intervention Occlude Left Lower Lobe - *Live Case*
- Intended Intervention PFO Closure using Gore Helex Septal Occluder Under GA and TEE Guidance - *Live Case*
- Pulmonary Valvuloplasty - Pulmonary Oedema Presentation
- Intended Intervention LAA Closure Using the Amplatzer Cardiac Plug - *Live Case*
- Transcatheter Alternatives in Sick Neonates With Coartation of the Aorta; Balloon Angioplasty vs Surgery for Native Coartation of the Aorta in Newborns
- **and many more.... Plus, live cases from other major meetings**

Presented by **CONGENITAL CARDIOLOGY TODAY**





**TINY HEARTS**

**inspired**

## **HYBRID LABS WITH ACCESS FOR BIG TEAMS.**

Fixing a heart from birth through adulthood takes big teams working together. So we examined the needs of leading clinicians when designing our hybrid solutions. The result: our Infinix™-i with 5-axis positioners and low profile detectors, stays out of the way, but right where needed, providing the best possible access to patients. To lead, you must first listen. [medical.toshiba.com](http://medical.toshiba.com)



[youtube.com/toshibamedical](http://youtube.com/toshibamedical)



[@ToshibaMedical](https://twitter.com/ToshibaMedical)